Cutaneous Leishmaniasis: An Overlooked Etiology of Midfacial Destructive Lesions

Elie Alam¹, Ossama Abbas², Roger Moukarbel¹*, Ibrahim Khalifeh³*

¹ American University of Beirut Medical Center, Department of Otolaryngology Head and Neck Surgery, Beirut, Lebanon, ² American University of Beirut Medical Center, Department of Dermatology, Beirut, Lebanon, ³ American University of Beirut Medical Center, Department of Pathology and Laboratory Medicine, Beirut, Lebanon

* These authors contributed equally to this work.

* rm17@aub.edu.lb (RM); ik08@aub.edu.lb (IK)

Abstract

Background

Midline destructive lesions of the face (MDL) have a wide range of etiologies. Cutaneous Leishmaniasis (CL) is rarely reported as a possible cause.

Methods

Fifteen patients with solitary nasal lesions caused by CL were studied. The clinical data, biopsies/scrapings and PCR were collected/performed. Ridley’s Pattern (RP) and Parasitic Index (PI) were documented.

Results

Patients’ age ranged from 1 to 60 years including 7 males and 8 females. The duration of the observed lesions ranged from 1 to 18 months. Clinically, the lesions showed 6 patterns varying from dermal erythematous papulonodular with no epidermal changes to destructive erythematous plaque with massive central hemorrhagic crust. The clinical impression ranged from neoplastic to inflammatory processes. RP varied among the cases [RP 3 (n = 6), RP 4 (n = 3), RP 5 (n = 6)]. All cases show low PI [PI 0 (n = 7), PI 1 (n = 6), PI 2 (n = 1), and PI 3 (n = 1)]. Higher PI was noted in the pediatric group [average age 24 years for PI 0–1 vs. 6.5 years for PI 2–3]. Molecular speciation showed Leishmania tropica (n = 13) and Leishmania major (n = 2). All the patients received Meglumine Antimonials (Glucantine) injections and had initial cure defined as complete scarring and disappearance of inflammatory signs within 3 months.

Conclusion

Leishmaniasis may cause MDL especially in endemic areas. PCR is instrumental in confirming the diagnosis. MDL caused by CL showed wide spectrum of clinical and microscopic presentation.
Author Summary

Midline destructive lesions of the face (MDL) involve a process that leads to ulceration and loss of the normal structure. The possible causes vary from infectious to neoplastic. Cutaneous Leishmaniasis (CL) is a neglected tropical disease that is transmitted through the bite of one of the female phlebotomine sandflies and is continuing to spread in endemic and non-endemic regions secondary to environmental and human made changes. CL is rarely reported as a possible cause of MDL. With the influx of over 1,500,000 refugees from Leishmania-endemic areas in Syria seeking shelter from the current conflict in their country, Lebanon, a Leishmania under-endemic country, is facing an epidemic outbreak of CL. In this study, we obtained clinical and laboratory data on 15 patients with solitary nasal lesions caused by CL. We concluded that Leishmaniasis may cause MDL especially in endemic areas and that PCR is instrumental in confirming the diagnosis. Moreover, MDL caused by CL showed wide spectrum of clinical and microscopic presentation.

Introduction

Midline destructive lesions of the face (MDL) were reported initially in 1897 and over time there have been many terms used to describe them [1]. The most common ones include idiopathic midline destructive disease, lethal midline granuloma, and idiopathic midline granuloma [2]. The various terms used all shared a common descriptive goal which is an ulcerative process leading to cartilage and epithelium loss along with crusting that leads to loss of nasal structure along with a resultant functional and cosmetic deformity.

The differential diagnosis of such lesions is wide and falls in mainly five categories; neoplastic, autoimmune, traumatic, infectious or idiopathic. Each category show some characteristic findings which can suggest it as being the cause, however many of those overlap and this can pose a significant diagnostic dilemma for the treating physician [3]. Despite advancements in the medical field, diagnosis of such lesions is often incorrect or missed. Moreover, the diagnosis of CL is widely overlooked. That's extremely noteworthy knowing that prompt diagnosis is crucial for the proper management and treatment of affected patients [3].

Leishmaniasis is categorized into three forms: visceral, mucocutaneous, and cutaneous leishmaniasis (CL). Leishmania is transmitted through the bite of one of the female phlebotomine sandflies that has been proven to be a vector of Leishmania. Globally, more than 90% of CL cases are reported in Afghanistan, Pakistan, Syria, Saudi Arabia, Algeria, and Iran [4, 5]. However, CL is a neglected tropical disease that is continuing to spread in endemic and non-endemic regions secondary to environmental and human made changes [6, 7]. CL in the Near East is predominantly caused by the Leishmania tropica species. Although not a cause of high mortality, CL can be chronic and disfiguring, producing multiple lesions that induce serious secondary infections and can involve vital sensory organs [5]. With the influx of over 1,500,000 refugees from Leishmania-endemic areas in Syria seeking shelter from the current conflict in their country; Lebanon, a Leishmania under-endemic country, is facing an epidemic outbreak of CL (8). In this study, we evaluated cases of CL affecting the midface in 15 subjects.

Materials and Methods

Ethics statement

This study was approved by the American University of Beirut Institutional Review Board who waived patient consent since the material deidentified by a third party. Patient data used in this
study was anonymized. The material was collected by another research group who approved this research [8].

Case selection
One hundred and sixty one Syrian refugees with CL were driven to nearby camp sites and outpatient centers and were examined. Thirty one of these subjects were found to have nasal lesions among other lesions, and 15 of them had nasal lesions exclusively. Clinical and epidemiological data collected included the lesion’s duration, size, type (wet: exudative or dry: non-exudative), anatomic location, number of lesions, gender, age, and geographic location. Cases were then blindly assessed by a dermatologist (OA) who described the lesions and suggested a differential diagnosis along with the most likely diagnosis. Each lesion was assigned an eruption type (erythematous plaque/patch, papule, papule/nodule, crust, ulcer verrucous and scar). A clinical impression was proposed to each lesion based on its clinical eruption pattern.

Microscopic examinations
On the outpatient department premises, a team of trained physicians collected multiple scrapings of the lesions and concurrent punch biopsies. Scrapings were made with the help of a scalpel, pushing in one direction until blood oozes from the inflamed border of the lesion. Multiple drops of the oozing blood were distributed on multiple glass slides. Four millimeter punch biopsies were taken from the border of the lesion of every patient. Skin scrapings were stored at room temperature, whereas biopsies were stored in tightly sealed formalin-filled tubes. A formalin-fixed paraffin-embedded (FFPE) tissue block was prepared from each punch biopsy. Biopsy slides were examined to assess Ridley’s Pattern (RP) and Parasitic Index (PI, Tables 1 and 2) [9].

Molecular testing
All included cases were sent for PCR confirmation according to a previously published standardized protocol [9]. For FFPE tissue blocks, DNA was extracted from ribbons originating from FFPE. For scraping, the DNA extraction was done using the Pel-Freez (Invitrogen, Carlsbad, CA) kit according to the manufacturer’s instructions. The DNA sample were incubated at 65°C for 30 minutes and then stored at 4°C until analyzed by PCR. The resultant DNA was then quantified using the Biomate spectrophotometer (Thermo, Glasgow, UK).

Inclusion/exclusion criteria
Only cases that are limited to the midface and had sufficient clinical data and available material for diagnostic confirmation by microscopic examination or PCR were included. All the remaining cases were excluded.

Table 1. Modified Ridley’s Parasitic Index for quantification of Amastigote Load.

| Parastitic Index | Number of Amastigotes per standard section |
|-----------------|--------------------------------------------|
| 6+              | ≥100,000                                   |
| 5+              | ≥10,000                                    |
| 4+              | ≥1000                                      |
| 3+              | ≥100                                       |
| 2+              | ≥10                                        |
| 1+              | ≥1                                         |

doi:10.1371/journal.pntd.0004426.t001
Results

Patient demographics

Patients’ age ranged from 1 to 60 years (mean: 22 years) and included 7 males and 8 females. The duration of the observed lesions ranged from 1 to 18 months (mean: 5.5 months). Just, 4 patients recalled an incident of an insect bite. Eight patients migrated from Aleppo, 6 from Homos and 1 from Damascus and all of them resided in different geographic locations within Lebanon. The duration since the patients moved to Lebanon ranged from 1 to 48 months (mean: 8 months).

Eruption type and clinical impression

The most frequent pattern of eruption was seen in five patients who had an erythematous plaque with central hemorrhagic crust, followed by 4 patients who had crusted erythematous plaque followed by 3 patients who had a scaly erythematous plaque/patch (see Table 3 and Fig 1). All lesions were dry, but one was wet and found to be Leishmania major.

Microscopic and molecular analysis

Microscopically, RP in Our patients ranged from RP 3 (n = 6), RP 4 (n = 3), RP 5 (n = 6, Fig 2). No amastigotes were identified in 7 patients (PI = 0) and the rest had a low PI: PI 1 (n = 6), PI 2 (n = 1), and PI 3 (n = 1). All cases were confirmed by PCR performed on biopsies. PCR performed on scrapings showed same results except for one patient where PCR failed due to bad quality of extracted DNA. Molecular subtype showed 13 patients to have Leishmania tropica whereas two patients had Leishmania major.

Treatment

Fourteen patients received Meglumine Antimoniate (Glucantime) intramuscularly, and one patient received intralesional injections. All patients had initial cure defined as complete scarring and disappearance of inflammatory signs within 3 months [10]. Group I represents an almost normal appearing skin biopsy with patches of collagen degeneration. Group II shows a predominant severe necrotizing process in the dermis. In Group III, the dermis is involved by a diffuse and heavy mixed inflammatory infiltrate. Group IV shows scattered Langhans giant cells and primitive epithelioid histiocytes. Well-formed granulomas and well-developed epithelioid histiocytes are prominent in Group V.

Discussion

The primary sign of CL (Old World) is usually a small erythema that develops after a variable period of time at the site where an infected sandfly has bitten the host. The usual progression of the disease is erythema that advances into a papule, then a nodule that gradually ulcerates.
### Table 3. Patients’ clinical microscopic and molecular information.

| Patient | Gender | Age (years) | Lesion Duration (months) | Dry/ Wet | PCR | Ridley’s pattern | PL | Molecular species | Eruption pattern | Differential Diagnosis | Favored Diagnosis |
|---------|--------|-------------|--------------------------|----------|-----|------------------|----|------------------|-----------------|---------------------|---------------------|
| Patient 1 | M | 6 | 9 | D | Positive | 5 | 1 | T | EPC | Wegener, Lymphoma, Pseudolymphoma, Mycobacterium | Wegener |
| Patient 2 | M | 12 | 4 | D | Positive | 5 | 0 | T | Erythematous Plaque with Multiple papular Component | LSLL | Leishmania |
| Patient 3 | M | 36 | 7 | D | Positive | 4 | 1 | T | EPC | LSLL | Leishmania |
| Patient 4 | M | 46 | 8 | D | Positive | 5 | 0 | T | EPC | LSLL | Leishmania |
| Patient 5 | F | 12 | 3.5 | D | Positive | 3 | 0 | T | SEP | LLS | Lupus |
| Patient 6 | M | 1 | 4 | D | Positive | 3 | 3 | T | CEP | LSLL | Leishmania |
| Patient 7 | F | 4 | 2 | D | Positive | 3 | 1 | T | Papulovesicular and Erythematous lesion | SLPG | Sarcoidosis |
| Patient 8 | F | 36 | 4 | D | Positive | 4 | 1 | M | CEP | LSLL | Leishmania |
| Patient 9 | M | 12 | 4.5 | W | Positive | 3 | 2 | M | EPC | LSLL | Leishmania |
| Patient 10 | F | 60 | 18 | D | Positive | 5 | 0 | T | CEP | LLS | Lupus |
| Patient 11 | F | 3 | 3 | D | Positive | 5 | 1 | T | SEP | LLS | Lupus |
| Patient 12 | F | 6 | 1 | D | Positive | 4 | 1 | T | EPC | Lymphoma, Pseudolymphoma, Sarcoidosis, Leishmania | Leishmania |
| Patient 13 | M | 34 | 11 | D | Positive | 5 | 0 | T | CEP | LSLL | Leishmania |
| Patient 14 | F | 55 | 3 | D | Positive | 3 | 0 | T | SEP | LLS | Lupus |
| Patient 15 | F | 5 | 1.5 | D | Positive | 3 | 0 | T | Erythematous Papulonodular with no Epidermal Changes | SLPG | Sarcoidosis |

Gender: M: Male, F: Female

Dry: Dry, W: Wet

Molecular Subtype: T: Tropica, M: Major

Eruption Pattern:

EPC: Erythematous Plaque with Central Hemorrhagic Crust

SEP: Scaly Erythematous Plaque/Patch

CEP: Crusted Erythematous Plaque

Differential Diagnosis:

LSLL: Leishmania, Lupus, Lupus Vulgaris, Sarcoidosis

LLS: Lupus, Lupus Vulgaris, Sarcoidosis

SLPG: Sarcoidosis, Lymphoma, Pseudolymphoma, Lupus

doi:10.1371/journal.pntd.0004426.t003
over a period of 2 weeks to 6 months to become the characteristic lesion of CL [11]. This usual course is self-limited within one year and is termed “annual sore”. Mucocutaneous leishmaniasis (New World) is characterized by the ability of the parasite to metastasise to mucous tissues by lymphatic or haematogenous dissemination. It is characterized by nasal inflammation and stuffiness followed by ulceration of the nasal mucosa and perforation of the septum [12].

Fig 1. Patients’ images. The most considered differential diagnosis list included Leishmania, Lupus, Lupus Vulgaris, Sarcoidosis whereby seven patients had lesions that fit this differential (see Table 3). doi:10.1371/journal.pntd.0004426.g001

Fig 2. Case with Ridley’s Patter 3 showing diffuse lymphoplasmacytic inflammatory infiltrates (A). Case with Ridley’s Pattern 5 showing well-formed granulomas (B). doi:10.1371/journal.pntd.0004426.g002
Leishmaniasis has been rarely described to be part of the differential of MDLs. The similarity in clinical symptoms and physical findings makes the accurate diagnosis of MDLs difficult to make. Despite diagnostic improvements and medical advancements, the etiology occasionally remains unidentified [3]. The most common causes of MDLs are nasal extranodal natural killer or T-cell lymphoma (NKTL), Wegener granulomatosis, and cocaine-induced midline destructive lesion. Other causes of MDLs exist but are less frequent and can be grouped into neoplastic, autoimmune, infectious, and idiopathic causes [3, 13, 14].

Crovetto-Martinez et al. described in a recent case report two patients suffering from mucocutaneous leishmaniasis whose presentation and evolution is similar to that of MDLs. The characteristic symptoms of both patients were rhinorrhea, bleeding, and crusting over the necrotic areas. Both cases were misdiagnosed and treated as Wegener’s Granulomatosis and NKTL. Moreover, due to therapeutic failure and disease progression, more extensive diagnostic measures were taken to properly diagnose and treat the lesions [15].

Parker et al. discussed the dilemma and difficulty of diagnosing midline lesions. The authors stressed on the importance of accurate diagnosis starting with the history and physical findings and how these findings can be attributed to a possible cause. In addition, they concluded that it is imperative to take multiple tissue specimens from possible sites for proper diagnosis and treatment [3].

In this study, we described 15 cases of Syrian Refugees in Lebanon presenting as facial midline lesions. Due to low PI in all the cases, the diagnosis of Leishmaniasis could have been overlooked; however the index of suspicion was high due to a CL breakout among the refugees. This in turn led to further confirmation via PCR.

As described in a previous study by Saab et al, the manifestations of CL are broad and may resemble not only inflammatory but also neoplastic diseases [16]. Similarly, in MDLs there is a variation in microscopic and clinical presentation. This is where PCR is instrumental even in cases where PI is low, especially when dealing with an endemic population, and knowing that low PI is a common presentation microscopically [9].

All patients in this study had a low PI (3 or less). When grouped into two sets, PI 0–1 and PI 2–3, to determine any difference in lesion duration and patient age between the 2 groups. The difference in lesion duration was not significant [6 months (PI 0–1) vs. 4 months (PI 2–3)]. However, the difference in patient age was significant [average age was 24 years for PI 0–1 versus 6.5 years for PI 2–3], whereby the pediatric group had a higher PI which represents the majority of our patients (9/15). Cutaneous lesions involving L. major typically manifest after a short incubation period of 1 week to 2 months with an exudative or ‘wet ulcer’. This study revealed that, in contrast to common thoughts that Leishmania major is characterized by wet lesions; one of our patients had a dry lesion and was found to be Leishmania major.

The most adopted treatment modalities of CL are Meglumine Antimonate (Glucantime) and Sodium Stibogluconate (Pentostam). Both are on the WHO essential drug list for CL. In our study we used the traditional treatment, Glucantime, because it is more readily available and less expensive than Pentostam [10].

In summary, this is to our knowledge the largest case series in the English literature describing CL as a cause of midline facial lesions. We were able to highlight the importance of having a high index of suspicion for Leishmaniasis and including it in the diagnosis of midline facial lesions especially in endemic areas. This holds true even in patients with a low PI whereby PCR confirmation becomes instrumental. This study further stresses on the variation in patients with midline facial CL clinically and microscopically, and also highlights the impact of human migration on CL evolution in non-endemic areas.
Author Contributions
Conceived and designed the experiments: EA IK RM. Performed the experiments: EA IK. Analyzed the data: EA IK RM OA. Contributed reagents/materials/analysis tools: EA IK RM OA. Wrote the paper: EA IK RM.

References
1. McBride P. Photographs of a case of rapid destruction of the nose and face. 1897. The Journal of laryngology and otology. 1991; 105(12):1120. PMID: 1787378
2. Borges A, Fink J, Villablanca P, Eversole R, Luftkin R. Midline destructive lesions of the sinonasal tract: simplified terminology based on histopathologic criteria. AJNR American journal of neuroradiology. 2000; 21(2):331–6. PMID: 10696019
3. Parker NP, Pearlman AN, Conley DB, Kern RC, Chandra RK. The dilemma of midline destructive lesions: a case series and diagnostic review. American journal of otolaryngology. 2010; 31(2):104–9. doi: 10.1016/j.amjoto.2008.11.010 PMID: 20015726
4. World Health O. Control of the leishmaniases. World Health Organization technical report series. 2010 (949):xii-xiii, 1–186, back cover.
5. Abd El-Salam NM, Ayaz S, Ullah R. PCR and microscopic identification of isolated Leishmania tropica from clinical samples of cutaneous leishmaniasis in human population of Kohat region in Khyber Pakhtunkhwa. BioMed research international. 2014; 2014:861831. doi: 10.1155/2014/861831 PMID: 24804255
6. Schonian G, Nasereddin A, Dinse N, Schwynchoch C, Schallig HD, Presber W, et al. PCR diagnosis and characterization of Leishmania in local and imported clinical samples. Diagnostic microbiology and infectious disease. 2003; 47(1):349–58. PMID: 12967749
7. Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert review of anti-infective therapy. 2010; 8(4):419–33. doi: 10.1586/eri.10.19 PMID: 20377337
8. Saroufim M, Charafejeddine K, Issa G, Khalifeh H, Habib RH, Berry A, et al. Ongoing epidemic of cutaneous leishmaniasis among Syrian refugees, Lebanon. Emerg Infect Dis. 2014; 20(10):1712–5. doi: 10.3201/eid2010.140288 PMID: 25279543
9. Yehia L, Adib-Houreih M, Raslan WF, Kibbi AG, Loya A, Firooz A, et al. Molecular diagnosis of cutaneous leishmaniasis and species identification: analysis of 122 biopsies with varied parasite index. Journal of cutaneous pathology. 2012; 39(3):347–55. doi: 10.1111/j.1600-0560.2011.01861.x PMID: 22335594
10. Negera E, Gadiya E, Hussein J, Engers H, Kuru T, Gedamu L, et al. Treatment response of cutaneous leishmaniasis due to Leishmania aethiopica to cryotherapy and generic sodium stibogluconate from patients in Silti, Ethiopia. Trans R Soc Trop Med Hyg. 2012; 106(8):496–503. doi: 10.1016/j.trstmh.2012.02.006 PMID: 22503475
11. Peters W K-KR, eds. The leishmaniases in biology and medicine. Clinical aspects and control. London: Academic Press; 1987.
12. Marsden PD. Mucosal leishmaniasis ("espundia" Escomel, 1911). Trans R Soc Trop Med Hyg. 1986; 80(6):859–76. PMID: 3037735
13. Westreich RW, Lawson W. Midline necrotizing nasal lesions: analysis of 18 cases emphasizing radiological and serological findings with algorithms for diagnosis and management. Am J Rhinol. 2004; 18(4):209–19. PMID: 15490567
14. Amengot M, Garcia-Lliberos A, Gomez MJ, Navarro A, Martorell A. Sinonasal involvement in systemic vasculitides and cocaine-induced midline destructive lesions: Diagnostic controversies. Allergy Rhinol (Providence). 2013; 4(2):e94–9.
15. Crovetto-Martinez R, Aguirre-Urizar JM, Orte-Aldea C, Araluçe-Iturbe I, Whyte-Orozco J, Crovetto-De la Torre MA. Mucocutaneous leishmaniasis must be included in the differential diagnosis of midline destructive disease: two case reports. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015; 119(1):e20–6. doi: 10.1016/j.oooo.2014.09.008 PMID: 25442251
16. Saab J, Fedda F, Khattab R, Yahya L, Loya A, Satti M, et al. Cutaneous leishmaniasis mimicking inflammatory and neoplastic processes: a clinical, histopathological and molecular study of 57 cases. Journal of cutaneous pathology. 2012; 39(2):251–62. doi: 10.1111/j.1600-0560.2011.01844.x PMID: 22168790